Lead Product(s) : Blosozumab
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TST002 (blosozumab) is a humanized anti-sclerostin mAb for osteoporosis and other bone loss diseases. It has a dual effect possessing both anabolic and anti-resorptive effects, which stimulates bone formation and inhibits bone absorption, enhancing bone ...
Product Name : TST002
Product Type : Antibody
Upfront Cash : Inapplicable
July 30, 2023
Lead Product(s) : Blosozumab
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Blosozumab
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TST002 (blosozumab) is a humanized anti-sclerostin mAb for osteoporosis and other bone loss diseases. It has a dual effect possessing both anabolic and anti-resorptive effects, which stimulates bone formation and inhibits bone absorption, enhancing bone ...
Product Name : TST002
Product Type : Antibody
Upfront Cash : Inapplicable
May 17, 2023
Lead Product(s) : Blosozumab
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Blosozumab
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TST002 (Blosozumab) is a humanized anti-sclerostin mAB for osteoporosis has a dual effect possessing both anabolic and anti-resorptive effects, which stimulates bone formation and inhibits bone absorption, resulting in fast increase in bone mineral densi...
Product Name : TST002
Product Type : Antibody
Upfront Cash : Inapplicable
April 28, 2022
Lead Product(s) : Blosozumab
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Denosumab
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HLX14 can specifically bind to RANKL and block the interaction between RANKL and RANK, expressed on the surface of osteoclasts, thus inhibiting RANKL/RANK-mediated differentiation, maturation and activation of osteoclasts, thereby reducing bone resorptio...
Product Name : HLX14
Product Type : Antibody
Upfront Cash : Inapplicable
September 11, 2020
Lead Product(s) : Denosumab
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable